Ji’an, Jiangxi, China, Dec. Feb. 21, 2022 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that six varieties of the Company’s products have been included in the first edition of the Catalog of Medicine for Patients Infected with COVID-19 (the “Catalogue”), which was published by the Beijing Health Commission on December 12, 2022. The products included are Banlangen granules, extract of potent loquat, pediatric paracetamol, Yinqiao vitamin C tablets, acetaminophen tablets and metamizole sodium tablets.
The Catalog complements the list of drugs recommended in the Ninth Edition of the National Diagnosis and Treatment Plan. The catalog recommends 67 kinds of traditional Chinese medicine products for six different kinds of medical symptoms, such as fever and sore throat, and recommends 41 varieties of Western medicine products for four kinds of clinical symptoms, such as cough and expectoration. In addition to hospitals, patients can also purchase medicines included in the catalog from channels such as retail pharmacies and e-commerce platforms according to their own needs.
Mr. Gang Lai, President and CEO of Universe Pharmaceuticals INC, said, “We are delighted to have our products included in the catalog. Currently, the order volume of our three products, Banlangen Granules, Strong Loquat Extract and Pediatric Paracetamol, continues to increase. We will optimize the supply chain system to meet the growing demand and strive to ensure sufficient supply of these three products for people to fight COVID-19 symptoms. »
About Universe Pharmaceuticals Inc.
Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical manufacturer and distributor in China. The Company specializes in the manufacture, marketing, sale and distribution of products derived from traditional Chinese medicine targeting the elderly with the aim of treating their physical conditions in the aging process and promoting their general well-being. The Company also distributes and sells biomedical drugs, medical devices, traditional Chinese medicine parts and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold to 30 provinces in China. For more information, visit the company’s website at http://www.universe-pharmacy.com/.
Forward-looking statements
All statements other than statements of historical facts in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections regarding future events and financial trends that the Company believes could affect its financial condition, results of operations, business strategy and his financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will be,” “expect,” “anticipate,” “goal,” “appreciation,” “intention,” “to plan,” “believe,” “potential,” “Carry on,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will prove to be correct, and the Company cautions investors that actual results may differ materially from anticipated results and encourages investors to consider other factors that could affect its future results in the company’s registration statement and in its other filings with the US Securities and Exchange Commission.
For more information please contact:
Ascent Investor Relations LLC
Tina Xiao
President
Phone: 917-609-0333
E-mail: tina.xiao@ascent-ir.com
0 Comments